Mode
Text Size
Log in / Sign up
Phase 4 Completed N=38 Randomized Treatment

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

Source: ClinicalTrials.gov NCT01427907 ↗
Enrolled (actual)
38
Serious AEs
4.0%
Results posted
Jan 2016
Primary outcomePrimary: Serum Phosphorus Levels — 4.6; 4.6 mg/dL

Summary

The purpose of this study is to demonstrate equivalence of calcium acetate oral solution and sevelamer carbonate in maintaining serum phosphorus levels This is a phase IV, multicenter, randomized, open-label, cross-over study to assess the equivalence of a liquid formulation of a calcium-based phosphate binder, COS, to sevelamer carbonate tablets, in hemodialysis dependent Chronic Kidney Disease subjects (CKD). The aim of the study is to maintain serum phosphorus level and establish equivalence between COS and sevelamer carbonate tablets.

Outcome Measures

OutcomeResultp-value
PRIMARY
Serum Phosphorus Levels
4.6; 4.6

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects ≥18 years of age able to give written informed consent to the study
  • Hemodialysis dependent chronic kidney disease stage 5D patients
  • Taking sevelamer carbonate tablets or sevelamer hydrochloride as phosphate binder monotherapy
  • Taking 3 or more sevelamer carbonate or sevelamer hydrochloride tablets per day

Exclusion Criteria

  • Estimated life expectancy of less than 6 months and for cancer patients, an Eastern Cooperative Oncology Group (ECOG) Performance Status >1
  • Active malignancy within the past 5 years. Basal or squamous cell skin cancer is not exclusionary. History of malignancy is not an exclusion
  • Known hypersensitivity reaction to calcium-based phosphate binders
  • Anticipated renal transplantation during the study
  • Pregnant or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01427907). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search